{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": {
    "pdf_name": "FlublokPI",
    "source_pdf": "data/clinical_files/FlublokPI.pdf",
    "total_pages": 5,
    "total_blocks": 73
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 3,
    "error": null
  },
  "supporting_snippets": [
    {
      "id": 1,
      "quote": "Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14 1). The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.",
      "relevance_explanation": "This quote directly states that Flublok Quadrivalent was evaluated in a trial (Study 6) against Fluarix Quadrivalent, a standard-dose quadrivalent influenza vaccine, supporting the claim."
    },
    {
      "id": 2,
      "quote": "Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator=U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.",
      "relevance_explanation": "This quote defines the comparator in the pivotal trial as Fluarix Quadrivalent, confirming that Flublok Quadrivalent was evaluated against Fluarix Quadrivalent."
    },
    {
      "id": 3,
      "quote": "The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol-defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 \u2013 [Attack rate Flublok Quadrivalent Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5).",
      "relevance_explanation": "This quote describes the design of the pivotal trial (Study 6), showing that Flublok Quadrivalent was directly compared to a comparator vaccine, which is defined elsewhere as Fluarix Quadrivalent."
    }
  ],
  "model_used": "gpt-4.1"
}